Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,898,741
  • Shares Outstanding, K 104,787
  • Annual Sales, $ 1,902 M
  • Annual Income, $ 235,240 K
  • EBIT $ -124 M
  • EBITDA $ -127 M
  • 60-Month Beta 0.39
  • Price/Sales 0.83
  • Price/Cash Flow 7.75
  • Price/Book 1.40

Options Overview Details

View History
  • Implied Volatility 104.12% (+2.16%)
  • Historical Volatility 76.10%
  • IV Percentile 80%
  • IV Rank 40.18%
  • IV High 193.83% on 07/24/25
  • IV Low 43.86% on 02/28/25
  • Expected Move (DTE 3) 2.06 (10.92%)
  • Put/Call Vol Ratio 0.99
  • Today's Volume 3,443
  • Volume Avg (30-Day) 3,087
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 108,146
  • Open Int (30-Day) 119,775
  • Expected Range 16.78 to 20.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.03
  • Number of Estimates 6
  • High Estimate -0.09
  • Low Estimate -1.88
  • Prior Year 1.50
  • Growth Rate Est. (year over year) -168.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.90 +11.51%
on 02/05/26
24.68 -23.66%
on 01/26/26
-2.29 (-10.84%)
since 01/23/26
3-Month
16.90 +11.51%
on 02/05/26
24.68 -23.66%
on 01/26/26
-0.07 (-0.37%)
since 11/24/25
52-Week
10.41 +80.89%
on 07/24/25
109.55 -82.80%
on 02/26/25
-86.72 (-82.15%)
since 02/24/25

Most Recent Stories

More News
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

- Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years - Company is...

SRPT : 18.84 (+3.97%)
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the TD Cowen 46 ...

SRPT : 18.84 (+3.97%)
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes...

SRPT : 18.84 (+3.97%)
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026

SRPT : 18.84 (+3.97%)
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

A t a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ...

SRPT : 18.84 (+3.97%)
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast...

SRPT : 18.84 (+3.97%)
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025 Preliminary...

SRPT : 18.84 (+3.97%)
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease

– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026

SRPT : 18.84 (+3.97%)
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference...

SRPT : 18.84 (+3.97%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously approved by the Compensation Committee...

SRPT : 18.84 (+3.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 19.96
2nd Resistance Point 19.55
1st Resistance Point 19.19
Last Price 18.84
1st Support Level 18.42
2nd Support Level 18.01
3rd Support Level 17.65

See More

52-Week High 109.55
Fibonacci 61.8% 71.68
Fibonacci 50% 59.98
Fibonacci 38.2% 48.28
Last Price 18.84
52-Week Low 10.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar